A randomized double-blinded placebo-controlled clinical trial of minodronate tablet in postmenopausal Chinese women with osteoporosis / 中华妇产科杂志
Chinese Journal of Obstetrics and Gynecology
;
(12): 346-351, 2022.
Article
in Chinese
| WPRIM
| ID: wpr-932444
ABSTRACT
Objective:
To verify the efficacy and safety of daily oral minodronate in postmenopausal women with established osteoporosis.Methods:
In this randomized, double-blinded, placebo-controlled trial, 262 postmenopausal women were enrolled. Patients were randomized to receive daily oral minodronate 1 mg with supplements of 500 mg calcium and 200 U vitamin D 3 ( n=130) or placebo ( n=132) with daily supplements of 500 mg calcium and 200 U vitamin D 3, for 48 weeks. The primary endpoint was the average bone mineral density (BMD) change in the lumbar vertebrae 48 weeks post-treatment. Secondary outcome measures was the incidence of vertebral fractures. Safety assessments included the rate of adverse events.Results:
At the end of 48 weeks treatment, the average BMD change rate from baseline were full analysis setresults:
(3.52±4.82)% in the minodronate group and (2.00±5.74)% in the placebo group; per-protocol setresults:
(3.99±5.05)% in the minodronate group and (2.07±6.20)% in the placebo group; the differences were all significant (all P<0.05). Vertebral fracture occured in 3 patients (2.3%, 3/132) in the placebo group, and 1 case (0.8%, 1/130) in the minodronate group ( P>0.05). The incidence of adverse events was 71.5% (93/130) in the minodronate group and 78.0% (103/132) in the placebo group ( P>0.05).Conclusion:
Minodronate is effective and safe in the treatment of postmenopausal osteoporosis without severe side effects.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Controlled clinical trial
/
Practice guideline
Language:
Chinese
Journal:
Chinese Journal of Obstetrics and Gynecology
Year:
2022
Type:
Article
Similar
MEDLINE
...
LILACS
LIS